Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Names New Executives, Denator Brings Aboard Sales Execs, King and Cassigneul Join PMC Board, and More

This article has been updated from a previous version to correct Stephen Pentoney's title. He has been appointed vice president of assay and reagent development at Illumina, not as VP of array biochemistry as the company had previously reported.
 
NEW YORK (GenomeWeb News) - Illumina has named Mostafa Ronaghi to the post of senior vice president and chief technical officer following the firm’s acquisition of Avatome, a DNA sequencing technologies startup formed just months ago. Ronaghi recently served as a senior research associate at the Stanford University Genome Technology Center. He also previously co-founded Swedish firm Pyrosequencing, later renamed Biotage. He was also a co-founder of ParAllele BioScience and Nextbio. Helmy Eltoukhy will also join the firm from Avantome as director of Avantome sequencing development
 
Illumina announced separately that it has appointed Stephen Pentoney to be vice president of assay and reagent development in the company’s Life Sciences Business Unit. In the new job, he will be responsible for leading assay application and development. Pentoney previously was involved in technology management and was a principal staff scientist at Beckman Coulter.
 

 
Denator has hired Katarina Alenäs to be European sales director, and it has hired John Lindsay of SciPartners to represent the company in the United States. Alenäs has worked in sales and marketing and product management for Agilent Technologies, Bayer Healthcare Diagnostics, and Aventis. Lindsay has over 25 years of experience in life sciences instrumentation sales, Denator said.
 

 
The Personalized Medicine Coalition has appointed David King and Pierre Cassigneul to its board of directors.
 
Cassigneul, who is president and CEO of XDx, formerly was an executive at Becton Dickinson, Stone Bridge Management, Ortho Diagnostics Systems, and Abbott Laboratories. David King is CEO and president of Laboratory Corporation of America, and he previously was a lawyer at Hogan & Hartson, where he was LabCorp’s outside counsel.
 

 
The Washington University School of Medicine in St. Louis has named Barry Sleckman to be director of the Division of Genomic Medicine. Sleckman studies DNA repair and the development of the early immune system. He has served fellowships at Brigham and Women’s Hospital, the Dana-Farber Cancer Institute and the Center for Blood Research, and he joined WUSTL as an assistant professor of pathology and immunology a decade ago.
 

 
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.